BioMarin Is Carrying The Biggest Target On Its Back, Morningstar Says
Executive Summary
BioMarin’s focus on rare diseases and gene therapies and expected financial growth make it a logical acquisition target for almost any large pharma, though Biogen, Amgen and Regeneron also offer a beneficial fit for many.